1Arnett DK. Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment[J]. Vascul Pharmacol, 2006, 44(2) :107-118.
2Stavroulakis GA, Makris TK. Krespi PG, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-eonverting enzyme gene polymorphism[J]. Cardiovase Drugs Ther. 2000, 14(4):427-432.
3Li X, Du Y. Huang X, et al. Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihy-pertensive therapy by angiotensin converting enzyme inhibitor [J]. J Cardiovasc Pharmacol Ther, 2003. 8(1):25-30.
4Ohmichi N. Iwai N, Uchida Y. et al. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype[J]. Am J Hypertens. 1997, 10(8): 951-955.
5Bis JC. Smith NL, Psaty BM, et al. Angiotensinogen Met235Thr polymorphism, angiotensin converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients[J]. Am J Hypertens, 20O3, 16(12) : 1011-1017.
6Mondorf UF, Russ A. Wiesemann A, et al. Contribution of angiotensin Ⅰ converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension[J]. Am J Hypertens, 1998, 11 (2):174-183.
7Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin Ⅱ receptor type 1 antagonist treatment in hypertensive patients[J]. Am J Hypertens, 2001, 19(10):1783-1787.
8Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with cande sartan[J]. Eur J Pharmacol.2002, 445(1-2): 151-152.
10Redon J. Luque Otero M, Martell N, et al. Renin angiotensin system gene polymorphisms: relationship with blood pressure and rnicroalbunlinuria in telmisartan treated hypertensive patients[J]. Pharmacogenomies J, 2005, 5(1): 14-20.
二级参考文献6
1Brown MJ.Causes of essential hypertension:can it be cured[J] ? J Hum Hypertens,1993,7:387-390.
2Hyndman ME,Parsons HG,Verma S,et al.The T786C mutation in endothelial nitric oxide synthase is associated with hypertension[J].Hypertension,2002,39:919-922.
3Lifton RP.Genetic determinant of human hypertension[J].Proc Natl Cad Sci USA,1955,92(19):8545-51.
4Nakayama M,Yasue H,Yoshimura,et al.T786C mutation in the 5'-flanking region of the endotheli al nitric oxide synthase gene is associated with coronary spasm[J].Circulation,1999,99:2664-2870.
5Tsujita Y,Baba S,Yamauchi R,et al.Association analyses between genetic polymorphisms of endothelial nitric oxide synthase gene and hypertension in Japanese:the suit study[J].J Hypertens,2001,19(11):1941-8.
6Kajiyama N,Saito Y,Miyamoto Y,et al.Lack of association between T786-C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene and essential hypertension [J].HypertensRes,2000,23(6):561-5.
